ORLANDO — The GIP/GLP-1 dual agonist tirzepatide reduced symptoms of obstructive sleep apnea and improved multiple cardiometabolic markers for adults with obesity and obstructive sleep apnea, according to data from the SURMOUNT-OSA trial.
In findings presented at the American Diabetes Association Scientific Sessions and simultaneously published in The New England Journal of Medicine, adults receiving tirzepatide (Zepbound, Eli Lilly) had greater reductions in apnea-hypopnea index (AHI) events per hour, which is a measure of severity of obstructive sleep apnea (OSA), compared with